Neurodegenerative disease-focused Yumanity Therapeutics Inc. will go public via a reverse-merger with struggling Proteostasis Therapeutics, Inc. in a deal Yumanity CEO Richard Peters describes as an effort to leverage common scientific expertise. However, he also said Yumanity was looking for a quick way to access the public capital markets after deciding to accelerate development of its potentially disease-modifying Parkinson’s disease drug, YTX-7739.
Yumanity Merges With Proteostasis To Accelerate Parkinson’s Therapy
Yumanity goes public by merging with Proteostasis; it is accelerating its Parkinson’s program because of mouse model data showing disease-modifying potential. Proteostasis will out-license its CF assets.
